Beta Bionics (BBNX) EBITDA (2024 - 2026)

Beta Bionics has disclosed EBITDA across 3 years of filings, most recently posting -$25.6 million for Q2 2026.

• In Q2 2026, EBITDA fell 28.71% year-over-year to -$25.6 million; the TTM figure through Jun 2026 stood at -$83.0 million (down 32.77% YoY), while the FY2025 annual figure was -$71.7 million, down 58.41% from the prior year.
• EBITDA came in at -$25.6 million for Q2 2026 at Beta Bionics, down from -$24.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.5 million in Q1 2024 to a low of -$25.6 million in Q2 2026.
• Average EBITDA over 3 years is -$16.7 million, with a median of -$16.6 million recorded in 2025.
• The largest YoY upside for EBITDA was 23.68% in 2025 against a maximum downside of 97.21% in 2025.
• Over 3 years, EBITDA stood at -$13.0 million in 2024, then declined by 23.68% to -$16.1 million in 2025, then sank by 58.63% to -$25.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$25.6 million in Q2 2026, -$24.3 million in Q1 2026, and -$16.1 million in Q4 2025.